Last reviewed · How we verify
EC Aspirin 325
EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation.
EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation. Used for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke), Reduction of cardiovascular risk in patients at risk for thrombotic events.
At a glance
| Generic name | EC Aspirin 325 |
|---|---|
| Sponsor | POZEN |
| Drug class | Antiplatelet agent / NSAID |
| Target | Cyclooxygenase (COX-1, COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly acetylates cyclooxygenase (COX) enzymes in platelets, blocking thromboxane A2 synthesis and preventing platelet aggregation. The enteric coating delays dissolution until the drug reaches the small intestine, reducing gastric irritation while maintaining antiplatelet efficacy. This formulation is designed to provide cardiovascular protection with improved gastrointestinal tolerability.
Approved indications
- Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)
- Reduction of cardiovascular risk in patients at risk for thrombotic events
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Bruising/bleeding
Key clinical trials
- A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (PHASE3)
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (PHASE3)
- Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers (PHASE3)
- A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EC Aspirin 325 CI brief — competitive landscape report
- EC Aspirin 325 updates RSS · CI watch RSS
- POZEN portfolio CI